全球輸液和口服鐵劑市場 - 熱門市場（2024-2029）

2023年全球輸液和口服鐵劑市場規模達76.6億美元。預計該市場將經歷強勁成長，到 2029 年複合年增長率將達到 13.47%。這種快速成長的主要驅動力是全球範圍內缺鐵 (ID) 和缺鐵性貧血 (IDA) 盛行率的不斷上升以及患者對有效治療方案的認識不斷提高。導致鐵缺乏的慢性疾病，如慢性腎臟病（CKD）、心臟衰竭、胃腸道疾病和癌症，尤其是手術患者的發生率不斷增加，也推動了市場的擴張。

推動市場成長的主要因素包括對無右旋糖酐鐵治療藥物的需求不斷增加以及透析和非透析腎病患者對鐵補充劑的需求不斷增加。該市場還受益於最新一代靜脈和口服鐵製劑的開發，這些製劑目前正在進行臨床試驗，旨在擴大適應症並改善治療結果。

Vifor Pharma 等市場領導者透過 Ferinject（在美國以 Injectafer 名稱出售）和 Venofer 等產品做出了重大貢獻，這些產品在透析患者中特別受歡迎。口服鐵劑市場由處方藥和非處方藥產品組成，儘管增速慢於靜脈鐵劑，但正在穩步擴張，由於其高成本效益，預計在新興和低收入國家將出現強勁增長。

市場成長不僅在已開發國家，在亞洲、非洲和拉丁美洲的新興國家也很顯著，這些國家缺鐵是嚴重的健康挑戰。醫院藥房營運創新和零售商的參與進一步推動了這種成長，提高了消費者的可及性和意識。

醫院藥房部門預計將發展壯大，因為它為鐵製劑提供專業服務。同時，零售商由於其即時的產品可用性和專家指導而繼續發揮重要作用。CKD 患者缺鐵的盛行率估計約為 70%，這凸顯了透過靜脈注射和口服鐵補充劑進行鐵治療的迫切需求。

該報告研究了全球輸液和口服鐵劑市場，提供了市場概述、給藥途徑趨勢、患者群體、分銷管道、應用、地區以及參與市場的公司概況。

目錄

第一章 輸液和口服鐵劑市場概況

第二章 輸液與口服鐵劑市場

第三章輸液和口服鐵劑市場收入預測（2023-2029年；十億美元）

• 世界:按管理途徑劃分的預計收入（2023-2029 年；十億美元）
• 世界:按患者群體劃分的預期收入（2023-2029 年；十億美元）
• 全球:按分銷管道劃分的預期收入（2023-2029 年；十億美元）
• 世界:按應用劃分的預計收入（2023-2029 年；十億美元）

第四章 主要地區概況

• 北美
• 美國
• 加拿大
• 歐洲
• 德國
• 英國
• 法國
• 義大利
• 西班牙
• 亞太地區
• 日本
• 中國
• 澳大利亞
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 中東/非洲
• 土耳其
• 南非
• 沙烏地阿拉伯

第五章輸液與口服鐵劑市場前景與機會

• IV 和口服鐵劑市場機會和趨勢
• 靜脈注射和口服鐵劑市場的驅動因素
• 靜脈注射和口服鐵劑市場的限制因素

第六章 輸液及口服鐵劑產業概況

• IV 和口服鐵劑市場 - 競爭格局
• 靜脈注射和口服鐵劑市場 – 主要供應商概況
• 靜脈注射和口服鐵劑市場—其他知名供應商
• IV 和口服鐵劑市場 – 關鍵策略建議

第7章附錄

The global IV and Oral Iron Drugs market, valued at $7.66 billion in 2023, will experience robust growth by 2029, expanding at a CAGR of 13.47%. This surge is primarily driven by the increasing prevalence of Iron Deficiency (ID) and Iron Deficiency Anemia (IDA) globally, coupled with a heightened awareness among patients about effective treatment options. The market's expansion is further propelled by the rising occurrence of chronic diseases such as Chronic Kidney Disease (CKD), heart failure, gastrointestinal disorders, and cancer, which can lead to iron deficiency, particularly in surgical patients.

Key factors fueling market growth include the growing demand for dextran-free iron therapeutics and the rising need for iron drugs among dialysis and non-dialysis kidney patients. The market also benefits from the development of investigational latest generation IV & oral iron drugs with broader indications and improved treatment outcomes.

Market leaders like Vifor Pharma are significantly contributing with products such as Ferinject (marketed as Injectafer in the US) and Venofer, which are gaining traction, especially among dialysis patients. The oral iron drug segment, comprising both prescription and OTC preparations, is expanding steadily, although slower than IV iron drugs, with significant growth in emerging and low-income countries due to their cost-effectiveness.

The market's growth is not just confined to developed nations; it's also significant in developing countries across Asia, Africa, and Latin America, where iron deficiency poses a severe health challenge. This growth is further augmented by innovations in hospital pharmacy practice and retail store involvement, facilitating accessibility and awareness among consumers.

The hospital pharmacies segment is expected to grow due to their specialized services in iron medicines. At the same time, retail stores continue to play a crucial role due to immediate product availability and expert guidance. The prevalence of iron deficiency in CKD patients, which is estimated to be around 70%, highlights the critical need for iron therapy with IV and oral iron drugs.

As the global IV & oral iron drugs market evolves, key vendors like Vifor Pharma, Daiichi Sankyo Group, AMAG Pharmaceuticals, and others focus on product innovations and expanded label approvals to meet the growing demands and adapt to new patient groups. The market, characterized by the presence of global, regional, and local players, is highly competitive with a wide array of branded and generic drug offerings.

KEY HIGHLIGHTS:

• The IV & oral iron drugs market represents a rapidly growing and most effective category of therapeutics that helps individuals with ID & IDA to improve their quality of life.
• By route of administration, the intravenous (IV) segment was valued at $4.40 billion in 2023. This growth mainly results from the expected launch of branded IV iron drugs in new markets and expanded indication approval for existing commercially available brands. One of the primary reasons for this significant growth rate is the increased uptake of branded IV drugs in the US and European markets.
• By patient group, the adult segment is going to witness notable growth during the forecast period. In 2023, the adult segment accounted for 83.33% of the global IV & oral iron drugs market. The segment is dominating the market due to the higher incidence/ prevalence of ID and IDA among elderly people across the world.
• By distribution channel, the hospital pharmacies segment is expected to grow at a significant CAGR. Hospital pharmacies offer iron drugs with adequate discounts and rebates. Thus offering a cost-effective way to minimize the burden on patients and healthcare systems.
• By application, In 2023, the nephrology segment accounted for 60.84% of the global IV & oral iron drugs market. The market for iron drugs in nephrology is increasing faster, and the trend is likely to continue during the forecast period due to the rising prevalence of CKD worldwide. The segment accounted for the largest market share owing to the increasing uptake of iron drugs to treat CKD.
• CSL Vifor, Covis Pharmaceuticals, Daiichi Sankyo, Akebia Therapeutics, Shield Therapeutics, and others are some of the leading players currently dominating the global IV & Oral iron drugs market. The major players focus on strategic acquisitions and collaborations with emerging players to enter the IV & Oral Iron Drugs market and to gain access to commercially launched products.

REPORT HIGHLIGHTS

PRODUCT SEGMENTATION & FORECAST

• Route of Administration
• Intravenous
• Oral
• Patient Group
• Adults
• Pediatrics
• Distribution Channel
• Hospital Pharmacies
• Offline Retail Pharmacies
• Online Channels
• Application
• Nephrology
• Obstetrics & Gynaecology
• Surgery
• Gastroenterology
• Oncology
• Heart Failure
• MARKET STRUCTURE
• Market Dynamics
• Competitive Landscape of IV & Oral Iron Drugs Market
• Key Vendors
• Other Prominent Vendors
• APPENDIX
• Research Methodology
• Abbreviations
• About Arizton

VENDORS LIST

• CSL Vifor
• Daiichi Sankyo
• Covis Pharmaceuticals
• Akebia Therapeutics
• Shield Therapeutics
• Pharmacosmos
• AbbVie
• Sanofi
• AOP Orphan Pharmaceuticals
• Azad Pharmaceuticals
• Pfizer
• Ciron Drugs & Pharmaceuticals
• Rockwell Medical
• Salveo Lifecare
• Sunny Pharmaceuticals
• Zydus LifeSciences
• Nippon Shinyaku
• Alinter Group
• Alora Pharmaceuticals
• DSE Healthcare
• GSK plc

TABLE OF CONTENTS

CHAPTER - 1: IV & Oral Iron Drugs Market Overview

• Executive Summary
• Key Findings

CHAPTER - 2: IV & Oral Iron Drugs Market

• GLOBAL: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)

CHAPTER - 3: IV & Oral Iron Drugs Market Segmentation Data

• GLOBAL: Projected Revenue by Route of Administration (2023-2029; $Billions)
• Intravenous
• Oral
• GLOBAL: Projected Revenue by Patient Group (2023-2029; $Billions)
• Adults
• Pediatrics
• GLOBAL: Projected Revenue by Distribution Channel (2023-2029; $Billions)
• Hospital Pharmacies
• Offline Retail Pharmacies
• Online Channels
• GLOBAL: Projected Revenue by Application (2023-2029; $Billions)
• Nephrology
• Obstetrics & Gynecology
• Surgery
• Gastroenterology
• Oncology
• Heart Failure

CHAPTER - 4: Key Regions Overview

• North America: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
• Projected Revenue of IV & Oral Iron Drugs Market in US
• Projected Revenue of IV & Oral Iron Drugs Market in Canada
• Europe: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
• Projected Revenue of IV & Oral Iron Drugs Market in Germany
• Projected Revenue of IV & Oral Iron Drugs Market in UK
• Projected Revenue of IV & Oral Iron Drugs Market in France
• Projected Revenue of IV & Oral Iron Drugs Market in Italy
• Projected Revenue of IV & Oral Iron Drugs Market in Spain
• APAC: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
• Projected Revenue of IV & Oral Iron Drugs Market in Japan
• Projected Revenue of IV & Oral Iron Drugs Market in China
• Projected Revenue of IV & Oral Iron Drugs Market in Australia
• Latin America: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
• Projected Revenue of IV & Oral Iron Drugs Market in Brazil
• Projected Revenue of IV & Oral Iron Drugs Market in Mexico
• Projected Revenue of IV & Oral Iron Drugs Market in Argentina
• Middle East & Africa: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
• Projected Revenue of IV & Oral Iron Drugs Market in Turkey
• Projected Revenue of IV & Oral Iron Drugs Market in South Africa
• Projected Revenue of IV & Oral Iron Drugs Market in Saudi Arabia

CHAPTER - 5: IV & Oral Iron Drugs Market Prospects & Opportunities

• IV & Oral Iron Drugs Market Opportunities & Trends
• IV & Oral Iron Drugs Market Drivers
• IV & Oral Iron Drugs Market Constraints

CHAPTER - 6: IV & Oral Iron Drugs Industry Overview

• IV & Oral Iron Drugs Market - Competitive Landscape
• IV & Oral Iron Drugs Market - Key Vendor Profiles
• IV & Oral Iron Drugs Market - Other Prominent Vendors
• IV & Oral Iron Drugs Market - Key Strategic Recommendations

CHAPTER - 7: Appendix

• Research Methodology
• Abbreviations
• About Arizton

List Of Exhibits

LIST OF EXHIBITS

Exhibit 1: Projected Revenues of IV & Oral Iron Drugs in Global ($ Bn)

Exhibit 2: Market Size & Forecast - Intravenous ($ Bn)

Exhibit 3: Market Size & Forecast - Oral ($ Bn)

Exhibit 4: Market Size & Forecast - Adults ($ Bn)

Exhibit 5: Market Size & Forecast - Pediatrics ($ Bn)

Exhibit 6: Market Size & Forecast - Hospital Pharmacies ($ Bn)

Exhibit 7: Market Size & Forecast - Offline Retail Stores

Exhibit 8: Market Size & Forecast - Online Channels ($ Bn)

Exhibit 9: Market Size & Forecast - Nephrology ($ Bn)

Exhibit 10: Market Size & Forecast - Obstetrics & Gynecology ($ Bn)

Exhibit 11: Market Size & Forecast - Surgery ($ Bn)

Exhibit 12: Market Size & Forecast - Gastroenterology ($ Bn)

Exhibit 13: Market Size & Forecast - Oncology ($ Bn)

Exhibit 14: Market Size & Forecast - Heart Failure ($ Bn)

Exhibit 17: Projected Revenues of IV & Oral Iron Drugs in North America ($ Bn)

Exhibit 18: Projected Revenues of IV & Oral Iron Drugs in US ($ Bn)

Exhibit 19: Projected Revenues of IV & Oral Iron Drugs in Canada ($ Bn)

Exhibit 20: Projected Revenues of IV & Oral Iron Drugs in Europe ($ Bn)

Exhibit 21: Projected Revenues of IV & Oral Iron Drugs in Germany ($ Bn)

Exhibit 22: Projected Revenues of IV & Oral Iron Drugs in UK ($ Bn)

Exhibit 23: Projected Revenues of IV & Oral Iron Drugs in France ($ Bn)

Exhibit 24: Projected Revenues of IV & Oral Iron Drugs in Italy ($ Bn)

Exhibit 25: Projected Revenues of IV & Oral Iron Drugs in Spain ($ Bn)

Exhibit 26: Projected Revenues of IV & Oral Iron Drugs in APAC ($ Bn)

Exhibit 27: Projected Revenues of IV & Oral Iron Drugs in Japan ($ Bn)

Exhibit 28: Projected Revenues of IV & Oral Iron Drugs in China ($ Bn)

Exhibit 29: Projected Revenues of IV & Oral Iron Drugs in Australia ($ Bn)

Exhibit 30: Projected Revenues of IV & Oral Iron Drugs in Latin America ($ Bn)

Exhibit 31: Projected Revenues of IV & Oral Iron Drugs in Brazil ($ Bn)

Exhibit 32: Projected Revenues of IV & Oral Iron Drugs in Mexico ($ Bn)

Exhibit 33: Projected Revenues of IV & Oral Iron Drugs in Argentina ($ Bn)

Exhibit 34: Projected Revenues of IV & Oral Iron Drugs in Middle East & Africa ($ Bn)

Exhibit 35: Projected Revenues of IV & Oral Iron Drugs in Turkey ($ Bn)

Exhibit 36: Projected Revenues of IV & Oral Iron Drugs in South Africa ($ Bn)

Exhibit 37: Projected Revenues of IV & Oral Iron Drugs in Saudi Arabia ($ Bn)

List Of Tables

LIST OF TABLES

Table 1: Key Market Trends in IV & Oral Iron Drugs Market

Table 2: Key Market Enablers in IV & Oral Iron Drugs Market

Table 3: Key Market Constraints in IV & Oral Iron Drugs Market

Table 4: Strategic Recommendations in IV & Oral Iron Drugs Market